Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regulus (RGLS)
NASDAQ:RGLS
Regulus (RGLS) Stock Price & Analysis
464 Followers
RGLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $3.79
Previous Close$1.65
Volume240.34K
Average Volume (3M)851.16K
Market Cap
$108.02M
Enterprise Value$11.87M
Total Cash (Recent Filing)$97.55M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 08, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding65,465,876
10 Day Avg. Volume874,559
30 Day Avg. Volume851,159
Standard Deviation0.29
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$12.25Price Target Upside642.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Regulus News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyRGLS8429 achieves significant increases in urinary polycystin levels and TKV reduction in 70% patients in Cohort 3.
Financial PositionRGLS is well-capitalized to deliver on key inflection points throughout 2024, and additional upside is expected from candidates developed using the microRNA targeting platform.
Regulatory PathwayManagement has already confirmed with the agency that an Accelerated Approval pathway is a possibility, which may allow for a rapid and cost-effective development path in this blockbuster indication.
Bears Say
Discontinued AssetsThe company discontinued a first-generation ADPKD asset due to off-target toxicity in animal studies.
Market ValuationDespite positive data from a newer asset with no safety issues, market valuation has not recovered.
Safety ConcernsThree discontinuations in the latest trial cohort due to various safety issues, including injection site reactions and abdominal pain.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGLS FAQ
What was Regulus’s price range in the past 12 months?
Regulus lowest stock price was $1.08 and its highest was $3.79 in the past 12 months.
What is Regulus’s market cap?
Currently, no data Available
When is Regulus’s upcoming earnings report date?
Regulus’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Regulus’s earnings last quarter?
Regulus released its earnings results on May 09, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.222 by -$0.068.
Is Regulus overvalued?
According to Wall Street analysts Regulus’s price is currently Undervalued.
Does Regulus pay dividends?
Regulus does not currently pay dividends.
What is Regulus’s EPS estimate?
Regulus’s EPS estimate is -$0.12.
How many shares outstanding does Regulus have?
Regulus has 65,465,870 shares outstanding.
What happened to Regulus’s price movement after its last earnings report?
Regulus reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.222. Following the earnings report the stock price went down -1.778%.
Which hedge fund is a major shareholder of Regulus?
Among the largest hedge funds holding Regulus’s share is RA Capital Management. It holds Regulus’s shares valued at 18M.
---
Regulus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.25 (642.42% Upside)
$12.25 (642.42% Upside)
Blogger Sentiment
Bullish
RGLS Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.79%
12-Months-Change
Fundamentals
Return on Equity
-46.75%
Trailing 12-Months
Asset Growth
208.36%
Trailing 12-Months
Company Description
Regulus
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
---
RGLS Earnings Call
Q3 2022
0:00 / 0:00
---
RGLS Stock 12 Month Forecast
Average Price Target
$12.25
▲(642.42% Upside)
Technical Analysis
Best Analysts Covering RGLS
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+14.92%
reiterated a buy rating 7 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +14.92% per trade.
---